Drug Class Detail

Drug Class VEGFR3 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Famitinib SHR1020 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Famitinib is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373).
Anlotinib AL3818|AL-3818 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Anlotinib (AL-3818) inhibits KDR (VEGFR2) and VEGFR3, thereby preventing angiogenesis and tumor cell growth (NCI Drug Dictionary).
Telatinib BAY 57-9352 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 BAY 57-9352 (Telatinib) inhibits VEGFR2, VEGFR3, PDGFR-beta, and KIT, which may result in decreased proliferation and angiogenesis in tumors expressing these factors (NCI Drug Dictionary).
Cediranib AZD-2171|Recentin KIT Inhibitor 48 VEGFR1 Inhibitor 4 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778).
XL647 KD019|Tesevatinib EGFR Inhibitor (Pan) 38 EPHB4 Inhibitor 6 HER2 Inhibitor 20 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 XL647 is an inhibitor of multiple receptor tyrosine kinases, including ERBB2 (HER2), EGFR, VEGFR2 and VEGFR3, and EphB4, potentially resulting in decreased tumor growth and angiogenesis (PMID: 17575237).
Molecular Profile Protein Effect Treatment Approaches